search
Back to results

Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
sitagliptin and acarbose
Sponsored by
Nanjing First Hospital, Nanjing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Participate voluntarily and sign the subject informed consent before the test.
  2. Patients with type 2 diabetes, aged 18-75 years, meeting the diagnostic criteria of WHO1999, have not been treated with any hypoglycemic drugs.
  3. No acute complications such as diabetic ketoacidosis and diabetic hyperosmolar syndrome.
  4. Subjects are able and willing to undergo FGM examination, diet and exercise regularly.

Exclusion Criteria:

  1. Patients allergic to insulin.
  2. Impaired liver and renal function, ALT 2.5 times higher than the upper limit of normal value;Serum creatinine was 1.3 times higher than the upper limit of normal.
  3. A history of drug abuse and alcohol dependence within the past 5 years.
  4. Systemic hormone therapy was used in recent 3 months.
  5. Patients with poor compliance and irregular diet and exercise.
  6. Patients with infection and stress within four weeks.
  7. Patients who cannot tolerate flash glucose mornitoring(FGM).
  8. Patients who are pregnant, nursing or preparing to become pregnant.
  9. Any other apparent condition or comorption as determined by the investigator, such as severe heart and lung disease, endocrine disease, neurological disease, tumor disease, other pancreatic disease, history of mental illness.

Sites / Locations

  • Gu Gao

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group A

Group B

Arm Description

Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.

Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.

Outcomes

Primary Outcome Measures

Glycemic variations
CV

Secondary Outcome Measures

Glycemic variations
TIR

Full Information

First Posted
April 14, 2021
Last Updated
August 30, 2021
Sponsor
Nanjing First Hospital, Nanjing Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05035849
Brief Title
Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose
Official Title
Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
January 30, 2020 (Actual)
Primary Completion Date
April 30, 2021 (Actual)
Study Completion Date
May 5, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nanjing First Hospital, Nanjing Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The aim of the study is to compare the FGM glycemic profiles in patients with type 2 diabetes mellitus treated with sitagliptin and acarbose.
Detailed Description
In this study, 60 patients with type 2 diabetes were randomly divided into group A or group B after stable glucose control. Flash Glucose Mornitoring(FGM) will be used in patients with two groups. Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks. The opposite therapy was true for patients in group B.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Patients in group A were given sitagliptin and metformin for the first two weeks, and then were treated with acarbose and metformin for the second two weeks. FGM was used to monitor glycemic variations during the whole four weeks.
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Patients in group B were given acarbose and metformin for the first two weeks, and then were treated with sitagliptin and metformin for the second two weeks.FGM was used to monitor glycemic variations during the whole four weeks.
Intervention Type
Drug
Intervention Name(s)
sitagliptin and acarbose
Intervention Description
One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
Primary Outcome Measure Information:
Title
Glycemic variations
Description
CV
Time Frame
Endpoint at the third month
Secondary Outcome Measure Information:
Title
Glycemic variations
Description
TIR
Time Frame
Endpoint at the third month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participate voluntarily and sign the subject informed consent before the test. Patients with type 2 diabetes, aged 18-75 years, meeting the diagnostic criteria of WHO1999, have not been treated with any hypoglycemic drugs. No acute complications such as diabetic ketoacidosis and diabetic hyperosmolar syndrome. Subjects are able and willing to undergo FGM examination, diet and exercise regularly. Exclusion Criteria: Patients allergic to insulin. Impaired liver and renal function, ALT 2.5 times higher than the upper limit of normal value;Serum creatinine was 1.3 times higher than the upper limit of normal. A history of drug abuse and alcohol dependence within the past 5 years. Systemic hormone therapy was used in recent 3 months. Patients with poor compliance and irregular diet and exercise. Patients with infection and stress within four weeks. Patients who cannot tolerate flash glucose mornitoring(FGM). Patients who are pregnant, nursing or preparing to become pregnant. Any other apparent condition or comorption as determined by the investigator, such as severe heart and lung disease, endocrine disease, neurological disease, tumor disease, other pancreatic disease, history of mental illness.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianhua Ma, MD
Organizational Affiliation
Nanjing First Hospital, Nanjing, Jiangsu, China, 210012
Official's Role
Study Chair
Facility Information:
Facility Name
Gu Gao
City
Nanjing
Country
China

12. IPD Sharing Statement

Learn more about this trial

Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose

We'll reach out to this number within 24 hrs